

MagForce

Steady progress

MagForce is moving forward with its strategy to drive uptake and acceptance (in the US and Europe) of its NanoTherm nanoparticle-based therapy for cancer. In Germany, Magforce has six centres commercially capable (three utilised, c50 patients to date) of treating glioblastoma (GBM) patients. To accelerate uptake of NanoTherm treatment in Europe, we expect Magforce to look to expand from Germany into other countries over six to 18 months. In the US, its subsidiary Magforce USA is in talks with the FDA to initiate a planned clinical trial in prostate cancer patients (potential launch in 2018). The company expects the trial to initiate in mid-2017; data are expected 12 months later. Our valuation is €225m (€8.8/share).

Year end	Revenue (€m)	PBT* (€m)	EPS* (€)	DPS (€)	P/E (x)	Yield (%)
12/14	0.0	(7.9)	(0.33)	0.0	N/A	N/A
12/15	2.6	(4.5)	(0.18)	0.0	N/A	N/A
12/16e	1.2	(7.0)	(0.27)	0.0	N/A	N/A
12/17e	3.5	(4.2)	(0.16)	0.0	N/A	N/A

Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments. Note: Figures above do not include MagForce USA.

First NanoActivators installed in the US

MagForce has installed the first NanoActivators (two out of four installed) in the US ahead of the planned prostate cancer trial. This machine is similar to those currently installed in Germany for GBM, with specific modifications for both the US market and treatment of prostate cancer. MagForce USA is in possession of four NanoActivators; we expect at least another one to be installed within the next six months for use in the forthcoming clinical trial.

Prostate IDE approval expected shortly

MagForce filed an investigational device exemption (IDE) in May 2015, which, if approved, would allow the planned pivotal prostate clinical trial to start in the US (the trial plans to assess NanoTherm therapy as focal treatment for prostate cancer). With investigators and two NanoActivators already in place, we believe the trial will start promptly on IDE approval; MagForce is in active dialogue with the FDA.

Expansion in Europe to drive uptake

In Europe, six NanoActivators are now installed in Germany and commercial GBM patients have received therapy at four centres to date. Cross-border travel for these patients has proven impractical, and as such Magforce plans to rapidly install more NanoActivators across Europe to allow patients to be treated within their own countries.

Valuation: rNPV of €225m (€8.8/share)

We value Magforce at €225m (€8.8/share). In the EU, we expect expansion from Germany into other EU markets starting late in 2017 and continued progress in the US towards a market launch in 2018. Sufficient patient recruitment is vital to the commercial success in both markets (assuming approval in the US).

Re-initiation of coverage

Healthcare equipment & services

15 May 2017

Price €8.07

Market cap €207m

\$1.1/€

Net cash (€m) at 30 June 2016 3.4

Shares in issue 25.6m


Free float 70%

Code MF6

Primary exchange Frankfurt (Xetra)

Secondary exchange N/A

Share price performance



% 1m 3m 12m

Abs 38.0 83.4 74.7

Rel (local) 31.3 67.5 34.9

52-week high/low €9.1 €4.0

Business description

MagForce is a German firm with a European approved nanotechnology-based therapy to treat brain tumours. NanoTherm therapy consists of nanoparticle injection into the tumour, activated by an external magnetic field, producing heat and thermally destroying or sensitising the tumour.

Next events

US prostate cancer IDE approval Mid-2017

Start of US prostate cancer trial Mid-2017

Further NanoActivator installations H217

Analysts

Dr Daniel Wilkinson +44 (0)20 3077 5734

Dr Susie Jana +44 (0) 20 3077 5700

healthcare@edisongroup.com

[Edison profile page](#)

**MagForce is a research client
of Edison Investment
Research Limited**

Investment summary

Company description: Advancing on all fronts

MagForce has an approved nanotechnology-based medical device treatment for brain cancer. MagForce's NanoTherm therapy is designed to directly affect the tumour from within, while sparing surrounding healthy tissue. Magnetic nanoparticles are directly injected into a tumour and are then heated in the presence of an external magnetic field generated by specialist equipment (NanoActivator). This can either sensitise a solid tumour for additional treatment, such as chemotherapy or radiotherapy, or thermally destroy it. The product is approved in Europe for the treatment of brain tumours, where management is working to drive uptake and acceptance of this therapy. NanoTherm therapy has the European CE mark (in 27 countries), so commercial patients can be treated at any of the centres. In addition, management is actively pursuing development in the US, with a clear path to market now established for prostate cancer, which could launch in 2018 and be a significant contributor to revenues in the longer term.

Valuation: Risk-adjusted NPV of €225m or €8.8/share

Our valuation is €225m or €8.8 per MagForce AG share, based on a risk-adjusted NPV analysis; this takes into account €3.4m net cash (€5m March convertible bond is netted out) held in MagForce AG at the end of June 2016, in addition to estimated net cash held in MagForce USA (which is not specifically disclosed in the financial statements – estimated at \$11m [€10m]). We present a base case in both the EU and the US where the focus is specifically on GBM and prostate cancer, respectively. The breakdown of our rNPV valuation, which uses a 12.5% discount rate, is shown in Exhibit 2.

Sensitivities: US progress and delivering in Europe

MagForce is subject to the usual risks associated with product development in healthcare, including clinical trial delays or failures, regulatory risks, competitor successes, partnering setbacks, financing and commercial risks. In the near term, defining the exact scope of the trials in the US, obtaining FDA approval for the trial design and starting trials will be critical. We expect updates on this process in coming months, with the pivotal prostate cancer trial expected to start by mid-2017. In addition, progress with the ongoing post-marketing GBM study in Europe and delivering on initial commercial revenues will help to increase confidence in management's targets.

Financials: Costs controlled to reduce cash burn

MagForce AG reported €3.4m cash at the end of June 2016, which combined with a €5m convertible bond (issued in March 2017) and a further €1.1m (shown as debt for illustrative purposes) should be sufficient to fund operations through to the end of 2017, including the redistribution of three German NanoActivators across Europe. In 2015, MagForce USA raised \$15m (1.5m shares at \$10/share) in a private placement; the leading investor was Mithril Capital Management. Following this fund-raise, MagForce AG owns 76.9% of MagForce USA. This cash should be sufficient to conduct the planned clinical study in prostate cancer. We note that as per the company accounts we do not consolidate the US into our financial model; however, we do include our assumed R&D, S&M and potential future sales revenue of MagForce USA in our valuation. Outstanding warrants of \$15m (1.5m shares) held by investors would dilute MagForce AG's holding in MagForce USA to 62.5% if exercised. Under the five-year strategic plan established in late 2013, MagForce AG (including Magforce USA) continues to target annual revenues of €100-150m by 2019. We are more cautious, assuming a slower initial NanoTherm sales ramp, and currently project that MagForce can achieve this target three years later.

First NanoActivators installed in the US

MagForce installed the first NanoActivator in the US in Washington and a second NanoActivator in Texas in readiness for the planned start of the registration clinical trial in prostate cancer. Prostate cancer in the US presents a significant market opportunity, more so than GBM, and strategically makes sense as a first US indication, in our view. The start of the prostate cancer clinical trial (the focal thermal ablation study) with MagForce's NanoTherm therapy will be dependent on securing IDE approval, which is anticipated in mid-2017 following filing in May 2015. Once approval is granted, we believe the trial should be able to start shortly thereafter. If the IDE approval is granted and the trial starts in a timely manner, we believe first prostate cancer sales are possible from 2018. On this basis, we expect at least one further installation in the near term and further installations of both the large and small NanoActivators in the future.

First installations in readiness for prostate cancer trial

In November 2015, MagForce announced that the first NanoActivator had been installed in the US ahead of the start of the planned prostate cancer clinical trial. This NanoActivator is one of four machines that MagForce AG sold to its affiliate MagForce USA. The first machine has been installed in Seattle, Washington, and a second machine was recently installed at CHRISTUS Santa Rosa Hospital in San Antonio, Texas where Ian M Thompson Jr, MD, the co-principal investigator, is based. The clinical site incorporates a clinical office and the NanoActivator treatment centre. We anticipate at least one further machine will be installed in the US in the near term, taking the installed base to three for the purposes of running clinical trials.

These NanoActivators are similar in size and design to the machines currently installed in Germany for the treatment of brain cancer, but have been modified to conform to US market standards. More importantly, the machines can also be used for the treatment of prostate cancer, to prove the concept of NanoTherm therapy in treating this disease. We assume that the treatment of brain tumours will not be pursued in the US until NanoTherm for prostate cancer is commercially launched.

MagForce USA is continuing to develop pNanoActivators (ambulatory for outpatient care) for prostate cancer. The prototype design is similar to a dentist's chair in appearance. We believe that MagForce will aim to sell, rather than place, these machines into clinics in future. The importance of these machines lies in their ability to be placed within smaller clinics, thus potentially widening outreach to the US patient pool in the longer term. MagForce AG will manufacture core components of the machine, while production of non-core components and assembly will be undertaken by MagForce USA.

Exhibit 1: Prototype concept design of the pNanoActivators



MagForce is developing significantly smaller pNanoActivators (ambulatory, for outpatient care), which it will aim to sell (rather than place) in the future. At the 2016 AGM, a concept design was presented, with these machines essentially equivalent in size to a dentist's chair. This design could then be later approved via the 510k route (with the original NanoActivator for the pre-market approval as the predicate device).

Source: Edison Investment Research, MagForce

IDE approval for prostate cancer trial expected mid-2017

NanoTherm therapy is regulated as a device, rather than as a drug in the US, and therefore follows a medical device regulatory route through to approval. As part of this pathway, in May 2015 MagForce filed an IDE with the US FDA. If approved, this will allow the first pivotal clinical trial with NanoTherm therapy to start in the US in prostate cancer. MagForce is currently working with the FDA and has updated preclinical study data conducted a decade ago to current FDA standards. In the last year, the company has already had a number of discussions with the FDA and obtained informal feedback on the submission.

Once approved, given two NanoActivators are already in place, the proposed focal thermal ablation registration trial could start shortly thereafter. MagForce anticipates the study to initiate by mid-2017. MagForce expects the trial to recruit up to 120 prostate cancer patients and to assess NanoTherm therapy as focal treatment for prostate cancer. Focal therapy aims to destroy localised tumours in the prostate in patients with intermediate-risk prostate cancer (those patients who are not severe enough to warrant aggressive therapy and instead are under active surveillance to monitor the tumour). By ablating the prostate cancer focally, MagForce anticipates that patients will be able to maintain active surveillance and avoid surgery and other treatment modalities which are associated with side effects such as impairment in urinary and sexual functions.

Assuming the trial takes around 12-18 months to complete, data could become available in 2018. This should be sufficient to support a pre-market approval application for the device (based on the larger NanoActivators), with the smaller ambulatory machines approved towards the end of the clinical trial via the 510k route (using the original NanoActivator as the predicate device). We assume approval and first sales from 2018 of the pNanoActivators, allowing time for filing and regulatory review following data in 2018. We assume that after the installation of the four larger NanoActivators (by the end of 2017) all future device sales will be the smaller pNanoActivators.

Potential future peak sales in 2022 of \$210m (€190m)

Based on the proposed design of the pNanoActivators, we assume that it should be possible to install 30 devices per year in the US at peak. However, we note that this number is difficult to predict at this stage and will depend on the successful uptake of the device (driven by the clinical trial data and the size of the salesforce). Without yet knowing the duration or number of sessions that might be needed in prostate cancer, we conservatively assume each prostate NanoActivator could treat around 150 patients per year (in line with GBM). A smaller quantity of nanoparticles will likely be required in prostate cancer; hence we assume a lower vial price of around a quarter of GBM, ie around \$6k per vial. This price would position NanoTherm competitively with brachytherapy. Each prostate NanoActivator could therefore generate revenues of almost \$1m per year, leading to a potential opportunity of \$210m (€190m).

Europe moves forward with first sales

First commercial treatments

In Europe, where NanoTherm therapy is already approved via a CE mark to treat brain cancers, MagForce has six NanoActivators installed in Germany (in Berlin, Münster, Kiel, Cologne, Frankfurt, and Göttingen). With these installations, MagForce now has the capacity to continue with commercial treatments and the ongoing post-marketing GBM study. During 2015, MagForce initiated the first commercial treatment of GBM patients in Germany. Commercial therapy is currently available at three centres (in Münster, Berlin and Cologne), with all three having already treated patients. Although only a handful of patients were treated during 2015 and 2016, MagForce is investing in its commercial development team to drive the near-term commercial treatment rate

through increasing its reach out to the medical community, patients and patient advocacy groups as well as working to streamline the reimbursement process. Additionally, the slow progress in Germany highlighted the reluctance of many of these seriously ill patients to travel to other countries for treatment; as such, MagForce now plans to roll out additional devices across Europe in order to improve patient access.

The current CE mark in Europe is for brain cancers, and NanoTherm therapy can therefore be used to treat primary and recurrent brain tumours. MagForce is focused on attracting patients from across the brain cancer spectrum, rather than just on recurrent disease, thereby enlarging the patient population who could benefit from this treatment.

Post-marketing GBM study ongoing

The post-marketing GBM study is still ongoing (the first patient was enrolled in March 2014). Although NanoTherm is already approved in Europe, the study was planned to drive wider acceptance, awareness and uptake of NanoTherm. Installation of the current NanoActivators in Germany, in addition to familiarisation with their operation, has been facilitated by this study. Although the study has yet to yield any data, the benefits are already being realised through commercial treatment of patients (around 50 patients to date). We do not expect any data in the near term from the study and as it is not required for any regulatory purposes we do not expect the data to have a significant impact on the uptake and use of NanoTherm therapy. Instead, we believe this will be realised through ongoing commercial efforts; however, lack of granularity with regards to future commercial strategy make this difficult to assess.

Broader European expansion in the future

We expect that MagForce will look to accelerate installations of NanoActivators outside of Germany this year, as physicians gain more experience of the therapy and more data become available. We believe that installing a further 20-25 NanoActivators across the major European countries over the next five to 10 years seems achievable. Each NanoActivator costs around €400k, which we capitalise as a tangible fixed asset, depreciating the cost over 10 years. We assume MagForce is able to recoup this initial outlay via an arrangement with the hospital where each large NanoActivator is placed through a pay per use fee. It could also adopt a standard leasing agreement over five years.

GBM in Europe could be around a €60m opportunity

Our European revenue forecasts are based on the number of NanoActivators that MagForce could install in Germany and Europe. Based on similar assumptions to the US in terms of each NanoActivator treating around 150 patients at peak per year and each vial of NanoTherm priced at €20k rather than €6k for prostate cancer due to higher quantity required for treatment of brain cancer, this would lead to annual revenues of around €3m per NanoActivator.

In Germany we assume three of the six NanoActivators will be redeployed to other European countries. With €3m of annual revenue possible from each machine (based on 150 patients at peak per year and each vial of NanoTherm priced at €20k), this therefore equates to c €10m of revenue possible in Germany alone in GBM.

Beyond Germany we continue to include a contribution from other countries, assuming installations occur more broadly in Europe. With understanding gained from marketing in Germany that seriously ill GBM patients are reluctant to travel across borders, the placement of devices throughout Europe is vital in driving revenues. We assume peak sales of c €65m in the broader EU assuming 20-25 machines are installed over the next five to 10 years and we expect the first revenues to begin to be booked in FY17. We expect three of the NanoActivators in Germany to be redeployed across separate European countries in FY17. These estimates suggest NanoTherm

therapy would be treating fewer than 4,000 GBM patients in Europe in the future per year at peak levels. This should be seen in the context of around 25k new cases of brain cancer in the EU5 (the United Kingdom, France, Germany, Italy and Spain) per year.

GBMs arise from astrocytes and are usually highly malignant due to the speed at which they grow. At any time a large number of cancer cells are dividing and expanding; this growth is driven by a substantial blood supply, which nourishes the tumour cells. GBMs can be divided into two types: the more common faster growing primary tumours and slower but still aggressive secondary tumours. Primary tumours make up about 90% of all GBMs and are the focus of MagForce's NanoTherm therapy.

Standard GBM treatment involves tumour resection followed by postoperative radiotherapy combined with temozolomide. GBM tumours consist of about 15% of all primary brain cancers. The [WHO](#) reported approximately 250,000 new cases of brain or nervous system cancer worldwide in 2012, while mortality was around 190,000. Survival rates are some of the lowest among all cancers (three-year survival of c 10%).

Prostate cancer development is a distinct possibility

With NanoTherm nanoparticle-based therapy for cancer prostate cancer now advancing in the US, this indication could also be developed in Europe, utilising data from the US to help secure approval. The smaller NanoActivators (pNanoActivators) currently under development by MagForce USA could potentially be sold in Europe in the future, helping to drive this market. At this early stage, we attribute no value to prostate cancer in Europe due to the company's focus on GBM in Europe and no information on timelines with regards to the indication.

After lung cancer, prostate cancer is the most common cancer among men. In 2012, worldwide there were 1.1m reported new cases of prostate cancer with [307.5 thousand deaths](#). Treatment of prostate cancer depends on the progression of the disease; for localised cancer, surgery is commonly utilised, with chemo, radiation, hormone and biologic therapy combinations also utilised for more advanced cases. Prostate cancer has surgical treatment rates of around [one in 10 patients](#), representing a significant patient population. Surgical treatments commonly involve a radical prostatectomy: the complete removal of the prostate including surrounding tissue. Two types exist: retropubic (incision in the abdomen) or perineal (incision in the area between the scrotum and anus) prostatectomy. Common problems after surgery include impotence, inguinal hernia (bulging of fat/small intestine through weak muscle) and leakage of urine.

MagForce's upcoming prostate cancer study in the US plans to enrol 120 patients who have grade 7 (Gleason score) prostate cancer and are under active surveillance. Grade 7 defines a moderate growing tumour, one that can be readily operated on. The NanoTherm therapy will be used to ablate cancer lesions.

NanoTherm therapy

The destruction or treatment of cancerous cells with heat is well established, commonly through laser or microwave irradiation. Current techniques can often be intrusive and can suffer from unfocused heat distribution. Cancer cells are more susceptible to heat than healthy cells; while it is dependent on cell type it is generally believed healthy cells can survive at temperatures around 42°C, temperatures at which cancerous cells undergo necrosis (cell death). Temperature increases up to approximately 43°C result in hyperthermia associated cell death, while temperatures above 43°C result in thermoablation, which causes irreversible destruction of both healthy and cancerous cells. MagForce's NanoTherm therapy is utilised to ablate cancerous cells at the core of a tumour while generating lower temperatures in the hyperthermia region on the edges of the tumour,

minimising healthy cell damage. The NanoTherm therapy consists of three main components: NanoTherm, NanoPlan and NanoActivator.

NanoTherm: Ferrofluid injected directly into the tumour

NanoTherm consists of magnetic nanoparticles suspended in a liquid (ferrofluid) that are injected directly into tumour tissue. These nanoparticles are activated with an alternating magnetic field; this activation generates heat. The nanoparticles consist of an iron oxide core with a patented aminosilane coating. These nanoparticles are suspended in water and form a colloidal dispersion.

Structure and stability of nanoparticles is dependent on their size and morphology. Different synthesis techniques may generate particles of similar size but varying magnetic properties. Manufacturing of nanoparticles produces a distribution of sizes; minimising this range allows more control over key properties and is vital in delivering consistent treatment.

The applied magnetic field from the NanoActivator gets converted to heat by the hysteresis of the magnetic nanoparticles. Magnetic hysteresis produces heat, which is undesirable in most applications; however, for the treatment of tumours this effect can be taken advantage of.

Thermal distribution of the nanoparticle heat can vary depending on the type of tissue, heating time and nanoparticle composition. A balance between heat generation in the particles and the flow to the surrounding tissues must be achieved. Along with the heterogeneity of tissues, nanoparticle distribution will vary across compartments of a tumour. Once injected into the tumour, the nanoparticles aggregate and have been shown to remain where they have been injected. These nanoparticles are then exposed to a magnetic field of enough strength to produce heat. This heat either kills the tumour cells or sensitises them to other treatments (radio therapy/chemotherapy).

NanoPlan and NanoActivator

NanoPlan is a software package that calculates the strength of magnetic field needed for the magnetic nanoparticles to reach the required temperature. The software takes into account the size and location of the tumour and the distribution of nanoparticles to determine the strength of the magnetic field. This information is critical for the correct application of the technology and is fed in from either magnetic resonance imaging or positron tomography data.

NanoActivator is a free-standing, room-sized device that generates and applies a magnetic field to a patient. This magnetic field induces an oscillation in the iron oxide nanoparticles, which in turn generate heat, which either kills or sensitises the tumour cells. To measure the exact temperature change, a thermometry catheter is inserted into the tumour via a minimally invasive surgical procedure alongside the administration of the nanoparticles. Alongside the original NanoActivator, MagForce is developing a more compact version for specific use in the US prostate market.

Study data

Data from the largest trial to date utilising NanoTherm therapy [was published in 2010](#). A total of 66 GBM patients were enrolled in a single-arm study in two centres. The trial utilised a combination of NanoTherm therapy and radiotherapy. The primary endpoint was overall survival following diagnosis of first tumour recurrence, with the secondary endpoint being overall survival after primary tumour diagnosis. The primary endpoint demonstrated a 13.4-month median overall survival, while secondary endpoint data demonstrated a 23.2-month median overall survival; no control arm was present in the study so it is difficult to compare both endpoints with other treatments. However, a [review of therapeutic options](#) demonstrates that the median overall survival for patients treated after reoccurrence falls between six and 12 months, and for patients after initial tumour diagnoses between 15 and 18 months. A trial cited by MagForce as a historical control

demonstrated that the median survival for 573 newly diagnosed patients utilising a combination of radiotherapy and temozolomide was 14.6 months.

Sensitivities

MagForce is subject to the usual risks associated with product development in healthcare, including clinical trial delays or failures, regulatory risks, competitor successes, partnering setbacks, financing and commercial risks.

In the near term, defining the exact scope of the trials in the US, obtaining FDA approval for the trial design and starting trials will be critical. We expect the pivotal prostate cancer trial to start in mid-2017; however, further delays would have an impact on our valuation, given the NanoTherm US prostate indication contributes ~56% to our valuation, or €4.9 share. In addition, progress with the ongoing post-marketing GBM study in Europe and delivering on initial commercial revenues will help to increase confidence in management's targets. Any delays could affect expected revenue generation and this could translate to further funding requirements.

Valuation

Our updated valuation is €225m or €8.8 per MagForce AG share, based on a risk-adjusted NPV analysis. It is centred on NanoTherm therapy, risk-adjusted to reflect the current development status and the respective core strategies for the EU and US. We value only GBM in the EU and prostate cancer in the USA, although we recognise MagForce's future intention to treat additional indications in each region. In each indication and region, our valuation includes our revenue forecasts and estimates for costs, including R&D and S&M. This includes €3.4m net cash held in MagForce AG at end June 2016, in addition to estimated net cash held in MagForce USA (which is not specifically disclosed in the financial statements). We utilise a \$1.1/€ spot rate. Note that while we value MagForce USA, as per company reporting, it is not consolidated into our financial model. The breakdown of our rNPV valuation, which uses a 12.5% discount rate, is shown in Exhibit 2.

Exhibit 2: MagForce AG risk-adjusted NPV valuation

Product	Indication	Launch	Peak sales (€m)	Peak sales (\$m)	NPV (€m)	Probability	MagForce AG beneficial interest	rNPV (€m)	rNPV/share (€)
NanoTherm EU	GBM - Germany	2015	10	11	30.4	100%	100%	30.4	1.3
	GBM - broader use	2017	65	72	88.7	65%	100%	57.7	2.3
NanoTherm US	Prostate cancer	2018	191	210	233.7	70%	77%	125.9	4.9
Net cash (AG)					3.4	100%	100%	3.4	0.1
Net cash (US)					10.0	100%	77%	7.7	0.3
Valuation					366.2			225.0	8.8

Source: Edison Investment Research. Note: Peak sales are rounded to the nearest €5m/\$5m for original currency.

In Germany, we assume three of the six NanoActivators will be redeployed to other European countries. With €3m of annual revenue possible from each machine (based on 150 patients at peak per year and each vial of NanoTherm priced at €20k), this therefore equates to c €10m of revenue possible in Germany alone in GBM.

Beyond Germany we include a contribution from other countries, assuming installations occur more broadly in Europe. With understanding gained from marketing in the German market that seriously ill GBM patients are reluctant to travel across borders, the placement of devices throughout Europe will be vital in driving revenues. We forecast peak sales in 2025 of c €65m in the broader EU, assuming 20-25 machines are installed over the next five to 10 years, and we expect revenues to begin to be booked in late FY17. We do not value prostate cancer in Europe; while potential remains in this indication, lack of clarity with regards to strategy make its value unclear at this time.

For the US opportunity, our valuation is wholly dependent on the prostate indication. While future value could be obtained from GBM and/or solid tumours, they are not the core focus in the US and, as such, timelines and strategy remain unclear. We believe this indication has a high probability of success (70%) due to the clinical benefit demonstrated in GBM. Additionally following the successful completion of US preclinical trials we believe the FDA will approve the clinical trial shortly. MagForce is prepared and ready to initiate the trial upon approval and we expect this could produce data in H118, with a potential launch by year end. We expect 30 pNanoActivators to be installed per year. We believe this is realistic given the time it has taken to place devices in Europe; we note that the cheaper compact pNanoActivators should make this task more straightforward than has been in the EU. We forecast peak sales of c \$210m (€191m) in 2025. We note significant assumed costs related to sales and marketing in our valuation. We assume €5m and €10m in S&M in 2017 and 2018, respectively.

We forecast that Magforce will receive approval for the use of its NanoActivators in prostate cancer in 2018, with a commercial launch shortly after. We predict peak sales of up to \$210m possible (€190m at current FX).

Financials

Our financial model incorporates 2014, 2015 and H116 reported financial results. MagForce reports financial results according to Handelsgesetzbuch (HGB), the German Commercial Code, as a small company; under these provisions majority or fully owned subsidiaries and affiliates are not consolidated. Additionally no cash flow statement is published. Hence the accounts represent MagForce AG alone and do not include any contribution from MagForce USA, which is majority owned (76.9%) by MagForce AG. Due to the lack of clarity regarding the US Magforce accounts, its cash and our projected revenue and cost assumptions are included in our valuation but not in our financial model.

In 2015 MagForce commenced initial commercial treatment with NanoTherm therapy in a handful of patients (number not disclosed), leading to small sales to the tune of €0.16m, which at a ~€20,000 cost per patient implies eight patients received treatment. Utilising the same assumptions, we estimate that up to 30 patients were treated in H116; however, due to uncertainty with regards to the breakdown of the revenues in H116, the number of patients treated could be lower. NanoTherm sales also include those on a cash basis and by reimbursement; as such the sale price will vary. In addition, during FY15 MagForce AG sold four NanoActivators to MagForce USA, which we estimate at around €600k each. FY15 revenues were €2.576m, with the bulk from the sale of these four machines (two of which were held on the balance sheet in inventories at the end of 2014). No sale of NanoActivators was booked in H116.

Under the five-year strategic plan established in late 2013, MagForce continues to target annual revenues of €100-150m in 2019. We believe this is an ambitious target and are slightly more cautious, assuming a slower initial NanoTherm sales ramp, currently projecting that MagForce can achieve this target three years later (2022).

With 2015 results, MagForce also recorded a €3m accounting income (non-cash) in operating income to reflect an expansion of MagForce USA's rights to NanoTherm therapy to now include Mexico and Canada. €6.9m was recorded in 2014 and €5.1m in 2013 related to the same out-licensing deal. We include these as exceptional items in our financial forecasts (hence they do not appear in normalised numbers). There was no income accounted for from the rights in Mexico and Canada in H116.

Operating expenses (which are classified according to nature rather than by function) have remained tightly controlled, with only €6.6m spent in 2015 (including €3.0m personnel expenses

and €3.2m other operating expenses). H116 operating expenses were €4.1m, a small decrease from H115 (€4.5m). Our 2016 operating expenses have been reduced to reflect the 2015/H116 trend, with total operating expenses for 2016 forecasted at €6.7m.

MagForce had reported cash and equivalents of €3.4m at end June 2016 versus €1.4m at end 2015. In addition, the company had no short-term loan receivables in H116 (disclosed in the notes to the financial statements) compared with €3.1m at end-2015. In the recent shareholder letter ([March 2017](#)), MagForce announced the issuance of a three-year €5m convertible bond with a 5% interest rate and a €5.0/share conversion price.

We forecast that the main driver of costs in 2017 and 2018 will be sales and marketing in Europe as MagForce looks to move into more markets; we predict these will be €2.5m and €3.5m, respectively. Our forecasts include an illustrative financing (which for simplicity we classify as long-term debt) of c €1m in 2017 (on top of the €5m convertible bond), to keep operations running until year end.

Cash and equivalents held in MagForce USA are not disclosed in the financial statements; we estimate these are currently c €10m (c \$11m) as we assume only minimal use of the proceeds from the \$15m fund-raise in August 2014, with spend only on purchasing the four NanoActivators and minimal operating expenses in the absence of any ongoing clinical trials in the US. We believe MagForce USA has sufficient funds in place to conduct the planned prostate trial once IDE approval is granted.

Exhibit 3: Financial summary

	€'000s	2014	2015	2016e	2017e	2018e
December		HGB	HGB	HGB	HGB	HGB
PROFIT & LOSS						
Revenue		0	2,576	1,150	3,450	6,486
Cost of Sales		(728)	(2,959)	(1,737)	(2,756)	(4,247)
Gross Profit		(728)	(383)	(587)	694	2,239
EBITDA		(7,962)	(4,421)	(6,696)	(3,849)	(4,337)
Operating Profit (before amort. and except.)		(8,175)	(4,871)	(7,017)	(4,227)	(4,785)
Intangible Amortisation		(6)	(5)	(5)	(2)	(0)
Exceptionals		6,900	3,000	0	0	0
Other		0	0	0	0	0
Operating Profit		(1,281)	(1,876)	(7,022)	(4,229)	(4,785)
Net Interest		274	329	0	0	0
Profit Before Tax (norm)		(7,901)	(4,542)	(7,017)	(4,227)	(4,785)
Profit Before Tax (reported)		(1,007)	(1,547)	(7,022)	(4,229)	(4,785)
Tax		(1)	(0)	0	0	0
Profit After Tax (norm)		(7,902)	(4,542)	(7,017)	(4,227)	(4,785)
Profit After Tax (reported)		(1,008)	(1,547)	(7,022)	(4,229)	(4,785)
Average Number of Shares Outstanding (m)		24.1	25.6	25.6	25.6	25.6
EPS - normalised (€)		(0.33)	(0.18)	(0.27)	(0.16)	(0.19)
EPS - normalised and fully diluted (€)		(0.33)	(0.18)	(0.27)	(0.16)	(0.19)
EPS - (reported) (€)		(0.04)	(0.06)	(0.27)	(0.17)	(0.19)
Dividend per share (€)		0.0	0.0	0.0	0.0	0.0
Gross Margin (%)		N/A	N/A	N/A	20.1	34.5
EBITDA Margin (%)		N/A	N/A	N/A	N/A	N/A
Operating Margin (before GW and except.) (%)		N/A	N/A	N/A	N/A	N/A
BALANCE SHEET						
Fixed Assets		15,707	19,533	20,042	21,365	22,312
Intangible Assets		11	7	2	0	0
Tangible Assets		3,697	4,494	5,007	6,332	7,279
Investments		12,000	15,033	15,033	15,033	15,033
Current Assets		12,999	5,325	5,714	7,058	8,844
Stocks		971	81	143	226	349
Debtors		0	910	630	1,890	3,554
Cash		11,153	1,393	2,000	2,000	2,000
Other		876	2,941	2,941	2,941	2,941
Current Liabilities		(4,081)	(1,779)	(1,572)	(2,202)	(3,034)
Creditors		(4,081)	(1,779)	(1,572)	(2,202)	(3,034)
Short term borrowings		0	0	0	0	0
Long Term Liabilities		(197)	(197)	(8,402)	(14,669)	(21,356)
Long term borrowings		0	0	(8,205)	(14,471)	(21,158)
Other long term liabilities		(197)	(197)	(197)	(197)	(197)
Net Assets		24,428	22,882	15,781	11,552	6,767
CASH FLOW						
Operating Cash Flow		(6,709)	(8,808)	(6,685)	(4,562)	(5,292)
Net Interest		0	329	0	0	0
Tax		0	(0)	0	0	0
Capex		(1,609)	(1,357)	(835)	(1,704)	(1,395)
Acquisitions/disposals		0	0	0	0	0
Financing		10,200	0	0	0	0
Dividends		0	0	0	0	0
Net Cash Flow		1,882	(9,837)	(7,520)	(6,266)	(6,686)
Opening net debt/(cash)		(9,271)	(11,153)	(1,393)	6,205	12,471
HP finance leases initiated		0	0	0	0	0
Other		(1)	77	(78)	(0)	(0)
Closing net debt/(cash)		(11,153)	(1,393)	6,205	12,471	19,158

Source: MagForce accounts, Edison Investment Research. Note: Historical and forecast cash flow numbers are Edison estimates as Magforce does not publish a statement of cash flows. All financial data is on an unconsolidated basis and does not include MagForce USA.

Contact details	Revenue by geography
Max-Planck-Strasse 3 12489 Berlin Germany +49 (0)30 3083 800 www.magforce.de	N/A
Management team	
CEO: Ben Lipps	CFO: Christian von Volkmann
Dr Lipps joined MagForce in September 2013, having previously been chair and CEO of Fresenius Medical Care since 1999. Dr Lipps led the research team that developed the first commercial hollow fibre artificial kidney at the end of the 1960s. Before joining Fresenius Group in 1985, Dr Lipps held several research management positions in various companies, among them Dow Chemical. He earned his master's and doctoral degrees at the Massachusetts Institute of Technology in chemical engineering.	Christian von Volkmann joined MagForce as CFO in May 2012. He was previously at Jerini, successfully contributing to the IPO in 2005, and was promoted to CFO in 2008 during the subsequent acquisition by Shire. Mr von Volkmann has more than 14 years of corporate finance and capital market transaction experience. He studied business administration at the Julius Maximilian University and is also a licensed certified public accountant in the US.
COO: Hoda Tawfik	
Professor Dr Hoda Tawfik has been at MagForce since May 2011. She has over 20 years' experience in the field of clinical development and medical affairs within the pharma/biotech industry. Before joining MagForce she worked at Medigene AG as head of the global clinical operations department and medical affairs for nine years. Dr Tawfik completed her pharmacy studies at the University of Cairo, and obtained a PhD in pharmacology and toxicology from the University of Düsseldorf.	
Principal shareholders	(%)
Avalon Capital One GMBH	37.00
Nanostart	9.80
Skagen funds	1.74
SW Mitchell Capital Ltd	1.63
Baring Fund Managers Ltd	1.27
M&G Securities Ltd	0.68
Forwards management LLC	0.68
Companies named in this report	
N/A	

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the [Financial Conduct Authority](#). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2017 Edison Investment Research Limited. All rights reserved. This report has been commissioned by MagForce and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE 2017. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE data is permitted without FTSE's express written consent.